title: Analysis of costs by CD4 count category for the darunavir/r 600/100 mg bid and control protease inhibitor arms of the POWER 1 and 2 trials.
abstract: BACKGROUND
  HIV-infected people with low CD4 counts are at higher risk of AIDS and incur increased health care costs from in-patient stays and medications.
  
  
  METHODS
  In the POWER 1 and 2 trials, patients were treated with optimized nucleoside reverse transcriptase inhibitors and optional enfuvirtide (T-20), plus darunavir/ritonavir (DRV/r) or control protease inhibitor (PI). UK data on costs of care by CD4 count were combined with the data on antiretroviral treatment use and CD4 counts from the POWER trials to calculate expected health care costs.
  
  
  RESULTS
  The mean annual UK cost of care (excluding antiretrovirals [ARVs]) was 23,780 pounds, 13,762 pounds, 7,032 pounds, and 7,032 pounds for patients with CD4 <50, 50-200, 200-350, and >350 cells/muL respectively. In the POWER trials, at week 48, the proportions of patients with CD4 counts in these categories were 7%, 36%, 29%, and 27% for the DRV/r arm versus 23%, 28%, 27%, and 22% for the control PI arm. The mean predicted annual per-patient cost of care was 11,170 pounds for DRV/r versus 12,873 pounds for control PI.
  
  
  CONCLUSIONS
  By raising CD4 counts to levels where the risk of AIDS events is reduced, DRV/r treatment is predicted to lower patient care costs for ARV-experienced, HIV-infected individuals in the first year of treatment.
authors.affiliation: Department of Pharmacology, University of Liverpool, Tibotec BVBA, United Kingdom. microhaart@aol.com
authors.forename: Andrew
authors.initials: A
authors.lastname: Hill
authors.forename: Lindsay
authors.initials: L
authors.lastname: Hemmett
authors.forename: Bernard
authors.initials: B
authors.lastname: Wilson
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000191:economics* / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D000069454:Darunavir; D000077560:Enfuvirtide; D005260:Female; D015700:HIV Envelope Protein gp41 / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010446:Peptide Fragments / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D019438:Ritonavir / Q000191:economics* / Q000627:therapeutic use; D013449:Sulfonamides / Q000191:economics* / Q000627:therapeutic use; D016896:Treatment Outcome; D006113:United Kingdom
chemical_list: D019380:Anti-HIV Agents; D015700:HIV Envelope Protein gp41; D017320:HIV Protease Inhibitors; D010446:Peptide Fragments; D018894:Reverse Transcriptase Inhibitors; D013449:Sulfonamides; D000077560:Enfuvirtide; D019438:Ritonavir; D000069454:Darunavir